P144. Sarcopenia and osteopenia in patients with Crohn's disease
I.A. Pintilie, I. Cracana, O. Jigaranu, C. Mihai, C. Cijevschi, University of Medicine and Pharmacy “Gr. T. Popa” Iasi, Institute of Gastroenterology, Iasi, Romania
Patients with Crohn's disease (CD) are prone to sarcopenia and osteopenia. Sarcopenia represents the loss of muscle mass and strength, and is considered as well as osteopenia secondary to malnutrition.
The aim of the study was to determine the prevalence of sarcopenia and osteopenia in CD patients and its relationship.
We included 48 cases with CD (23 female/25 male; median age of 40 years ±15; body mass index (BMI) 20.36±3.6) and 20 healthy volunteers (10 female/10 male; median age 40 years ±15; BMI 23.2±2.7). Sarcopenia was assessed by grip strength (estimate muscle strength) and dual-energy x-ray absorptiometry (DXA) (estimate lean body mass) and defined as a skeletal muscle index (SMI) below 5.45 kg/m2 for women and 7.26 kg/m2 for men. Osteopenia was defined as a T-score for bone mineral density (BMD) below −1.0 measured by DXA.
We found sarcopenia in 56.2% of CD patients and osteopenia in 47.9% vs 15% and 5% of controls, respectively (P < 0.01). HGS, SMI as well as BMD was significantly lower in patients with CD than in controls (35 kg ±5 vs. 50 kg ±10; 5.9 kg/m2 ±1.2 vs. 6.4 kg/m2 ±1.5; −1.7 g/cm2 ±0.6 vs. 0.9 g/cm2 ±0.3; P < 0.01). Sarcopenic patients had significantly (P < 0.01) lower BMI (19.64 versus 21.9) than non-sarcopenic patients; 74% of sarcopenic patients were also osteopenic.
The prevalence of sarcopenia and osteopenia is high in CD patients. These two phenomens may share similar mechanisms. Screening for sarcopenia and osteopenia may play an important role in the evaluation of CD patients.